TY - JOUR
T1 - Building the Future Therapies for Down Syndrome
T2 - The Third International Conference of the T21 Research Society
AU - Dierssen, Mara
AU - Herault, Yann
AU - Helguera, Pablo
AU - Martinez de Lagran, Maria
AU - Vazquez, Anna
AU - Christian, Bradley
AU - Carmona-Iragui, Maria
AU - Wiseman, Frances
AU - Mobley, William
AU - Fisher, Elizabeth M. C.
AU - Brault, Veronique
AU - Esbensen, Anna
AU - Jacola, Lisa M.
AU - Potier, Marie Claude
AU - Hamlett, Eric D.
AU - Abbeduto, Leonard
AU - del Hoyo Soriano, Laura
AU - Busciglio, Jorge
AU - Iulita, Maria Florencia
AU - Crispino, John
AU - Malinge, Sebastien
AU - Barone, Eugenio
AU - Perluigi, Marzia
AU - Costanzo, Floriana
AU - Delabar, Jean Maurice
AU - Bartesaghi, Renata
AU - Dekker, Alain D.
AU - De Deyn, Peter
AU - Fortea Ormaechea, Juan
AU - Shaw, Patricia A.
AU - Haydar, Tarik F.
AU - Sherman, Stephanie L.
AU - Strydom, Andre
AU - Bhattacharyya, Anita
PY - 2021/5/20
Y1 - 2021/5/20
N2 - Research focused on Down syndrome has increased in the last several years to advance understanding of the consequences of trisomy 21 (T21) on molecular and cellular processes and, ultimately, on individuals with Down syndrome. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. The Third International Conference of T21RS, held June 6-9, 2019, in Barcelona, Spain, brought together 429 scientists, families, and industry representatives to share the latest discoveries on underlying cellular and molecular mechanisms of T21, define cognitive and behavioral challenges and better understand comorbidities associated with Down syndrome, including Alzheimer's disease and leukemia. Presentation of cutting-edge results in neuroscience, neurology, model systems, psychology, cancer, biomarkers and molecular and phar-ma-cological therapeutic approaches demonstrate the compelling interest and continuing advancement in all aspects of understanding and ameliorating conditions associated with T21.
AB - Research focused on Down syndrome has increased in the last several years to advance understanding of the consequences of trisomy 21 (T21) on molecular and cellular processes and, ultimately, on individuals with Down syndrome. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. The Third International Conference of T21RS, held June 6-9, 2019, in Barcelona, Spain, brought together 429 scientists, families, and industry representatives to share the latest discoveries on underlying cellular and molecular mechanisms of T21, define cognitive and behavioral challenges and better understand comorbidities associated with Down syndrome, including Alzheimer's disease and leukemia. Presentation of cutting-edge results in neuroscience, neurology, model systems, psychology, cancer, biomarkers and molecular and phar-ma-cological therapeutic approaches demonstrate the compelling interest and continuing advancement in all aspects of understanding and ameliorating conditions associated with T21.
KW - Down syndrome
KW - Intellectual disability
KW - Language impairment
KW - Mouse models
KW - Neurodevelopmental disorders
KW - Alzheimer’
KW - s disease
KW - Biomarkers
KW - Trisomy 21 Research Society
KW - ALZHEIMERS-DISEASE
KW - GENE DOSAGE
KW - ADULTS
KW - DYSFUNCTION
KW - BIOMARKER
U2 - 10.1159/000514437
DO - 10.1159/000514437
M3 - Article
SN - 1661-8769
SP - 1
EP - 17
JO - Molecular Syndromology
JF - Molecular Syndromology
ER -